Product and Company News from the 7/22 News Brief

Biopharmaceutical company QLT announced that it has received final approval from the FDA to market Aczone (dapsone) Gel, for the topical treatment of acne vulgaris.

July 22, 2005

9:15 pm

Product News

Biopharmaceutical company QLT announced that it has received final approval from the FDA to market Aczone (dapsone) Gel, for the topical treatment of acne vulgaris.

Company news

Allergan and Pharmacopeia have reached an agreement to research compounds for age-related macular degeneration (AMD). Allergan seeks to strengthen its ocular diseases franchise via possible future acquisitions of Pharmacopeia’s novel compounds targeting angiogenesis.

AstraZeneca has agreed to pay up to $340m in cash and conditional milestone payments to Avanir, to license compounds for cardiovascular disease.

From Our Partners

Omnichannel activation without omniburden

Partner Content

Omnichannel activation without omniburden

Explore solutions for practically implementing omnichannel approaches into your go-to-market activation.

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.